Product NewsClinical Diagnostics
Reducing LOS and Improving MI Diagnosis Using Guidance-Acceptable cTn Assays
15 Oct 2015
Katherine Soreng, PhD, Director of Clinical and Scientific Marketing at Siemens Healthcare Diagnostics, discusses the use of troponin as a marker of myocardial damage and its appropriate use in MI diagnosis. Learn how you can reduce length of patient stay and improve the earlier diagnosis of MI with guideline-acceptable assays.
About the company
Siemens Healthineers
Siemens Healthcare is dedicated to helping you get the most out of your investment throughout the entire product life cycle and beyond. We understand that investments in healthcare technology today will have profound effects on both your patients and your business for years to come. Our goal is to enable you to take technology further, profitability higher, and patient care to the next level.
